Table Info

Table 2.

Summary of studies concerning oligoprogressive EGFR mutated NSCLC

Reference	Study	Period	Enrolled patients	Treatments	Results (months)	Toxicity > 2
Shukuya et al. [81], 2011	Retrospective	2002–2009	17	TKI + RT to CNS lesions	mPFS 2.5, mOS 13.4	None
Weickhardt et al. [82], 2012	Retrospective	2005–2011	23	TKI + LAT	mPFS1 13.8, mPFS2 6.2	None
Qiu et al. [78], 2017	Retrospective	2009–2014	46	LT + TKI	mOS (after LT) 13.0, mPFS (after LT) 7.0, 2-years OS 65.2%	G3 pneumonitis 4.3%
Chan et al. [79], 2017	Retrospective	2013–2015	25	LAT vs. CHT	mOS 28.2 vs. 14.7, mPFS 7.0 vs. 4.1	1 G3 oesophagitis
Xu et al. [76], 2019	Retrospective	2011–2016	206	TKI + LAT	mPFS 10.7, mOS 37.4	G3 pneumonitis 1.5%
Borghetti et al. [77], 2019	Retrospective	2010–2016	106	RT concomitant/after TKI	mOS 23.0, 1-year OS 76.3%, 2-years OS 48.6%, 3-years OS 29.5%	3 G3 toxicity cases
Guo et al. [80], 2019	Retrospective	2017–2018	97	Osimertinib +/– SBRT (on residual disease after 1st/2nd PD)	mPFS 17.0 vs. 11.0	Not reported

mPFS1: median PFS from initiations to TKI to PD or death; mPFS2: median PFS from the time of first progression; PD: Progression Disease; SBRT: stereotactic body radiation therapy

Declarations

Author contributions

FDP and FP: Data curation, Methodology, Writing—original draft. A Bruni and MT: Conceptualization, Supervision, Validation, Writing—review & editing, Validation. A Benini: Writing—review & editing. FL: Writing—review & editing, Validation. All authors read and approved the submitted version.

Conflicts of interest

MT received speakers’ and consultants’ fee from Astra-Zeneca, Pfizer, Eli-Lilly, BMS, Novartis, Roche, MSD, Boehringer Ingelheim, Otsuka, Takeda, Pierre Fabre, Amgen, Merck, Sanofi. MT received institutional research grants from Astra-Zeneca, Boehringer Ingelheim. A Bruni reported travel grants from AstraZeneca, MSD, Ipsen. Other authors have nothing to disclose.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al.; ESMO Guidelines Committee. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv192–237. Erratum in: Ann Oncol. 2019;30:863–70. [DOI] [PubMed]

Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al.; Spanish Lung Cancer Group. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361:958–67. [DOI] [PubMed]

Giaj-Levra N, Giaj-Levra M, Durieux V, Novello S, Besse B, Hasan B, et al.; European Organization for Research and Treatment of Cancer-Lung Cancer Group. Defining synchronous oligometastatic non-small cell lung cancer: a systematic review. J Thorac Oncol. 2019;14:2053–61. [DOI] [PubMed]

Dingemans AC, Hendriks LEL, Berghmans T, Levy A, Hasan B, Faivre-Finn C, et al. Definition of synchronous oligometastatic non-small cell lung cancer-a consensus report. J Thorac Oncol. 2019;14:2109–19. [DOI] [PubMed]

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al.; Spanish lung cancer group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239–46. [DOI] [PubMed]

Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A. 2008;105:2070–5. [DOI] [PubMed] [PMC]

Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al.; FLAURA Investigators. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113–25. [DOI] [PubMed]

Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al.; FLAURA Investigators. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382:41–50. [DOI] [PubMed]

Baumann M, Krause M. Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results. Radiother Oncol. 2004;72:257–66. [DOI] [PubMed]

10.

Chinnaiyan P, Huang S, Vallabhaneni G, Armstrong E, Varambally S, Tomlins SA, et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res. 2005;65:3328–35. [DOI] [PubMed]

11.

Moschini I, Dell’Anna C, Losardo PL, Bordi P, D’Abbiero N, Tiseo M. Radiotherapy of non-small-cell lung cancer in the era of EGFR gene mutations and EGF receptor tyrosine kinase inhibitors. Future Oncol. 2015;11:2329–42. [DOI] [PubMed]

12.

Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al.; ESMO Guidelines Committee. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:358–76. [DOI] [PubMed]

13.

Laurie SA, Banerji S, Blais N, Brule S, Cheema PK, Cheung P, et al. Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer. Curr Oncol. 2019;26:e81–93. [DOI] [PubMed] [PMC]

14.

Valeriani M, Detti B, Fodor A, Caini S, Borghesi S, Trippa F, et al. Radiotherapy at oligoprogression for metastatic castration-resistant prostate cancer patients: a multi-institutional analysis. Radiol Med. 2022;127:108–16. [DOI] [PubMed]

15.

Nicosia L, Franceschini D, Perrone-Congedi F, Casamassima F, Gerardi MA, Rigo M, et al. A multicenter LArge retrospectIve daTabase on the personalization of stereotactic ABlative radiotherapy use in lung metastases from colon-rectal cancer: the LaIT-SABR study. Radiother Oncol. 2022;166:92–9. [DOI] [PubMed]

16.

Masini C, Iotti C, De Giorgi U, Bellia RS, Buti S, Salaroli F, et al. Nivolumab in combination with stereotactic body radiotherapy in pretreated patients with metastatic renal cell carcinoma. results of the phase II NIVES study. Eur Urol. 2022;81:274–82. [DOI] [PubMed]

17.

Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol. 2020;38:2830–8. [DOI] [PubMed] [PMC]

18.

Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2018;4:e173501. [DOI] [PubMed] [PMC]

19.

Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8–10. [DOI] [PubMed]

20.

Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, et al. Characterisation and classification of oligometastatic disease: a European society for radiotherapy and oncology and European organisation for research and treatment of cancer consensus recommendation. Lancet Oncol. 2020;21:e18–28. [DOI] [PubMed]

21.

Lievens Y, Guckenberger M, Gomez D, Hoyer M, Iyengar P, Kindts I, et al. Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document. Radiother Oncol. 2020;148:157–66. [DOI] [PubMed]

22.

Gomez DR, Tang C, Zhang J, Blumenschein GR Jr, Hernandez M, Lee JJ, et al. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol. 2019;37:1558–65. [DOI] [PubMed] [PMC]

23.

Ashworth AB, Senan S, Palma DA, Riquet M, Ahn YC, Ricardi U, et al. An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. Clin Lung Cancer. 2014;15:346–55. [DOI] [PubMed]

24.

Blumenthaler AN, Antonoff MB. Classifying oligometastatic non-small cell lung cancer. Cancers (Basel). 2021;13:4822. [DOI] [PubMed] [PMC]

25.

Campo M, Al-Halabi H, Khandekar M, Shaw AT, Sequist LV, Willers H. Integration of stereotactic body radiation therapy with tyrosine kinase inhibitors in stage IV oncogene-driven lung cancer. Oncologist. 2016;21:964–73. [DOI] [PubMed] [PMC]

26.

Yang JJ, Chen HJ, Yan HH, Zhang XC, Zhou Q, Su J, et al. Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer. Lung Cancer. 2013;79:33–9. [DOI] [PubMed]

27.

Cheung P. Stereotactic body radiotherapy for oligoprogressive cancer. Br J Radiol. 2016;89:20160251. [DOI] [PubMed] [PMC]

28.

Bartholomew C, Eastlake L, Dunn P, Yiannakis D. EGFR targeted therapy in lung cancer; an evolving story. Respir Med Case Rep. 2017;20:137–40. [DOI] [PubMed] [PMC]

29.

Rajasekaran R, Sethumadhavan R. In silico identification of significant detrimental missense mutations of EGFR and their effect with 4-anilinoquinazoline-based drugs. Appl Biochem Biotechnol. 2010;160:1723–33. [DOI] [PubMed]

30.

Karachaliou N, Fernandez-Bruno M, Bracht JWP, Rosell R. EGFR first- and second-generation TKIs-there is still place for them in EGFR-mutant NSCLC patients. Transl Cancer Res. 2019;8:S23–47. [DOI] [PubMed] [PMC]

31.

Wang S, Li J. Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer. Onco Targets Ther. 2019;12:6535–48. [DOI] [PubMed] [PMC]

32.

Papini F, Sundaresan J, Leonetti A, Tiseo M, Rolfo C, Peters GJ, et al. Hype or hope-can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC? Crit Rev Oncol Hematol. 2021;166:103454. [DOI] [PubMed]

33.

Recondo G, Facchinetti F, Olaussen KA, Besse B, Friboulet L. Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI? Nat Rev Clin Oncol. 2018;15:694–708. [DOI] [PubMed]

34.

Ramalingam SS, Jänne PA, Mok T, O’Byrne K, Boyer MJ, Von Pawel J, et al. Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15:1369–78. [DOI] [PubMed]

35.

Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18:1454–66. [DOI] [PubMed]

36.

Yang JC, Sequist LV, Geater SL, Tsai CM, Mok TS, Schuler M, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015;16:830–8. [DOI] [PubMed]

37.

Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer. 2019;121:725–37. [DOI] [PubMed] [PMC]

38.

Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, et al.; AURA3 Investigators. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376:629–40. [DOI] [PubMed] [PMC]

39.

Papadimitrakopoulou VA, Mok TS, Han JY, Ahn MJ, Delmonte A, Ramalingam SS, et al. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Ann Oncol. 2020;31:1536–44. [DOI] [PubMed]

40.

Ramalingam SS, Cheng Y, Zhou C, Ohe Y, Imamura F, Cho BC, et al. Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study. Ann Oncol. 2018;29:viii740. [DOI]

41.

Rangachari D, To C, Shpilsky JE, VanderLaan PA, Kobayashi SS, Mushajiang M, et al. EGFR-mutated lung cancers resistant to osimertinib through EGFR C797S respond to first-generation reversible EGFR inhibitors but eventually acquire EGFR T790M/C797S in preclinical models and clinical samples. J Thorac Oncol. 2019;14:1995–2002. [DOI] [PubMed] [PMC]

42.

Chic N, Mayo-de-Las-Casas C, Reguart N. Successful treatment with gefitinib in advanced non-small cell lung cancer after acquired resistance to osimertinib. J Thorac Oncol. 2017;12:e78–80. [DOI] [PubMed]

43.

Niederst MJ, Hu H, Mulvey HE, Lockerman EL, Garcia AR, Piotrowska Z, et al. The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies. Clin Cancer Res. 2015;21:3924–33. [DOI] [PubMed] [PMC]

44.

Nishino M, Suda K, Kobayashi Y, Ohara S, Fujino T, Koga T, et al. Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitro. Lung Cancer. 2018;126:149–55. [DOI] [PubMed]

45.

Fu K, Xie F, Wang F, Fu L. Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. J Hematol Oncol. 2022;15:173. [DOI] [PubMed] [PMC]

46.

Deng L, Kiedrowski LA, Ravera E, Cheng H, Halmos B. Response to dual crizotinib and osimertinib treatment in a lung cancer patient with MET amplification detected by liquid biopsy who acquired secondary resistance to EGFR tyrosine kinase inhibition. J Thorac Oncol. 2018;13:e169–72. [DOI] [PubMed]

47.

York ER, Varella-Garcia M, Bang TJ, Aisner DL, Camidge DR. Tolerable and effective combination of full-dose crizotinib and osimertinib targeting MET amplification sequentially emerging after T790M positivity in EGFR-mutant non-small cell lung cancer. J Thorac Oncol. 2017;12:e85–8. [DOI] [PubMed]

48.

Araki T, Kanda S, Horinouchi H, Ohe Y. Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance. Jpn J Clin Oncol. 2023;53:547–61. [DOI] [PubMed] [PMC]

49.

Oxnard GR, Hu Y, Mileham KF, Husain H, Costa DB, Tracy P, et al. Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib. JAMA Oncol. 2018;4:1527–34. [DOI] [PubMed] [PMC]

50.

Piper-Vallillo AJ, Sequist LV, Piotrowska Z. Emerging treatment paradigms for EGFR-mutant lung cancers progressing on osimertinib: a review. J Clin Oncol. 2020;38:25. [DOI] [PubMed]

51.

Xi YZ, Xie L, Tan XW, Zeng SL. Transformation of adenocarcinoma to squamous cell carcinoma as a source of EGFR-TKI resistance: a case report and literature review. Front Oncol. 2022;12:942084. [DOI] [PubMed] [PMC]

52.

Schoenfeld AJ, Chan JM, Kubota D, Sato H, Rizvi H, Daneshbod Y, et al. Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line osimertinib in EGFR-mutant lung cancer. Clin Cancer Res. 2020;26:2654–63. [DOI] [PubMed] [PMC]

53.

Reck M, Mok TSK, Nishio M, Jotte RM, Cappuzzo F, Orlandi F, et al.; IMpower150 Study Group. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med. 2019;7:387–401. [DOI] [PubMed]

54.

Nogami N, Barlesi F, Socinski MA, Reck M, Thomas CA, Cappuzzo F, et al. IMpower150 final exploratory analyses for atezolizumab plus bevacizumab and chemotherapy in key NSCLC patient subgroups with EGFR mutations or metastases in the liver or brain. J Thorac Oncol. 2022;17:309–23. [DOI] [PubMed]

55.

Couñago F, Luna J, Guerrero LL, Vaquero B, Guillén-Sacoto MC, González-Merino T, et al. Management of oligometastatic non-small cell lung cancer patients: current controversies and future directions. World J Clin Oncol. 2019;10:318–39. [DOI] [PubMed] [PMC]

56.

Park K, Yu CJ, Kim SW, Lin MC, Sriuranpong V, Tsai CM, et al. First-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in Asian patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer: the ASPIRATION study. JAMA Oncol. 2016;2:305–12. [DOI] [PubMed]

57.

Giraud N, Abdiche S, Trouette R. Stereotactic radiotherapy in targeted therapy treated oligo-metastatic oncogene-addicted (non-small-cell) lung cancer. Cancer Radiother. 2019;23:346–54. [DOI] [PubMed]

58.

Passaro A, Leighl N, Blackhall F, Popat S, Kerr K, Ahn MJ, et al. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. Ann Oncol. 2022;33:466–87. [DOI] [PubMed]

59.

Zheng L, Wang Y, Xu Z, Yang Q, Zhu G, Liao XY, et al. Concurrent EGFR-TKI and thoracic radiotherapy as first-line treatment for stage IV non-small cell lung cancer harboring EGFR active mutations. Oncologist. 2019;24:1031–e612. [DOI] [PubMed] [PMC]

60.

Jia W, Guo H, Jing W, Jing X, Li J, Wang M, et al. An especially high rate of radiation pneumonitis observed in patients treated with thoracic radiotherapy and simultaneous osimertinib. Radiother Oncol. 2020;152:96–100. [DOI] [PubMed]

61.

Zhou K, Cai X, Wang X, Lan X, Zhang X. Efficacy and safety of WBRT+EGFR-TKI versus WBRT only in the treatment of NSCLC patients with brain metastasis: an updated meta-analysis. Thorac Cancer. 2022;13:563–70. [DOI] [PubMed] [PMC]

62.

Guimond E, Tsai CJ, Hosni A, O’Kane G, Yang J, Barry A. Safety and tolerability of metastasis-directed radiation therapy in the era of evolving systemic, immune, and targeted therapies. Adv Radiat Oncol. 2022;7:101022. [DOI] [PubMed] [PMC]

63.

Al-Halabi H, Sayegh K, Digamurthy SR, Niemierko A, Piotrowska Z, Willers H, et al. Pattern of failure analysis in metastatic EGFR-mutant lung cancer treated with tyrosine kinase inhibitors to identify candidates for consolidation stereotactic body radiation therapy. J Thorac Oncol. 2015;10:1601–7. [DOI] [PubMed]

64.

Gomez DR, Blumenschein GR Jr, Lee JJ, Hernandez M, Ye R, Camidge DR, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016;17:1672–82. [DOI] [PubMed] [PMC]

65.

Hu F, Xu J, Zhang B, Li C, Nie W, Gu P, et al. Efficacy of local consolidative therapy for oligometastatic lung adenocarcinoma patients harboring epidermal growth factor receptor mutations. Clin Lung Cancer. 2019;20:e81–90. [DOI] [PubMed]

66.

Zeng Y, Ni J, Yu F, Zhou Y, Zhao Y, Li S, et al. The value of local consolidative therapy in osimertinib-treated non-small cell lung cancer with oligo-residual disease. Radiat Oncol. 2020;15:207. [DOI] [PubMed] [PMC]

67.

Smith CP, Xiang M, Yoon SM, Lee A, Ruan D, Goldman JW, et al. Brief report: severe pneumonitis after combined thoracic radiotherapy and osimertinib. JTO Clin Res Rep. 2023;4:100468. [DOI] [PubMed] [PMC]

68.

Wang XS, Bai YF, Verma V, Yu RL, Tian W, Ao R, et al. Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated non-small cell lung cancer. J Natl Cancer Inst. 2023;115:742–48. Erratum in: J Natl Cancer Inst. 2023;115:773. [DOI] [PubMed] [PMC]

69.

Khan TM, Verbus EA, Gandhi S, Heymach JV, Hernandez JM, Elamin YY. Osimertinib, surgery, and radiation therapy in treating patients with stage IIIB or IV non-small cell lung cancer with EGFR mutations (NORTHSTAR). Ann Surg Oncol. 2022;29:4688–9. [DOI] [PubMed]

70.

Siva S, Solomon BJ. Metastatic ablation in epidermal growth factor receptor mutated oligometastatic non-small cell lung cancer-upfront or outback after systemic tyrosine kinase inhibitors? Int J Radiat Oncol Biol Phys. 2023;116:481–2. [DOI] [PubMed]

71.

Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, et al.; ALEX Trial Investigators. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377:829–38. [DOI] [PubMed]

72.

Magnuson WJ, Lester-Coll NH, Wu AJ, Yang TJ, Lockney NA, Gerber NK, et al. Management of brain metastases in tyrosine kinase inhibitor-naive epidermal growth factor receptor-mutant non-small-cell lung cancer: a retrospective multi-institutional analysis. J Clin Oncol. 2017;35:1070–7. [DOI] [PubMed]

73.

Majem M, Juan O, Insa A, Reguart N, Trigo JM, Carcereny E, et al. SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018). Clin Transl Oncol. 2019;21:3–17. [DOI] [PubMed] [PMC]

74.

Wang L, Jiao F, Dong L, Li Q, Liu G, Hu X. Lobectomy can improve the survival of patients with non-small cell lung cancer with lung oligometastatic. Front Surg. 2021;8:685186. [DOI] [PubMed] [PMC]

75.

Takahashi Y, Adachi H, Mizukami Y, Yokouchi H, Oizumi S, Watanabe A. Patient outcomes post-pulmonary resection for synchronous bone-metastatic non-small cell lung cancer. J Thorac Dis. 2019;11:3836–45. [DOI] [PubMed] [PMC]

76.

Xu Q, Liu H, Meng S, Jiang T, Li X, Liang S, et al. First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease. J Cancer. 2019;10:522–9. [DOI] [PubMed] [PMC]

77.

Borghetti P, Bonù ML, Giubbolini R, Levra NG, Mazzola R, Perna M, et al. Concomitant radiotherapy and TKI in metastatic EGFR- or ALK-mutated non-small cell lung cancer: a multicentric analysis on behalf of AIRO lung cancer study group. Radiol Med. 2019;124:662–70. [DOI] [PubMed]

78.

Qiu B, Liang Y, Li Q, Liu G, Wang F, Chen Z, et al. Local therapy for oligoprogressive disease in patients with advanced stage non-small-cell lung cancer harboring epidermal growth factor receptor mutation. Clin Lung Cancer. 2017;18:e369–73. [DOI] [PubMed]

79.

Chan OSH, Lee VHF, Mok TSK, Mo F, Chang ATY, Yeung RMW. The role of radiotherapy in epidermal growth factor receptor mutation-positive patients with oligoprogression: a matched-cohort analysis. Clin Oncol (R Coll Radiol). 2017;29:568–75. [DOI] [PubMed]

80.

Guo T, Ni J, Yang X, Li Y, Li Y, Zou L, et al. Pattern of recurrence analysis in metastatic EGFR-mutant NSCLC treated with osimertinib: implications for consolidative stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2020;107:62–71. [DOI] [PubMed]

81.

Shukuya T, Takahashi T, Naito T, Kaira R, Ono A, Nakamura Y, et al. Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure. Lung Cancer. 2011;74:457–61. [DOI] [PubMed]

82.

Weickhardt AJ, Scheier B, Burke JM, Gan G, Lu X, Bunn PA Jr, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol. 2012;7:1807–14. [DOI] [PubMed] [PMC]